Washington, DC 20006-5349
HELPLINE
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free…
This week, mesothelioma clinicians and researchers have come together in Lille, France, for the International Mesothelioma Interest Group‘s biannual meeting known as iMig to discuss…
UPDATE: On March 10, 2023, Merck announced through a press release that its Phase 3 study met its primary endpoint of overall survival which was…
Last week, the Polaris Group announced positive results of its Phase 2/3 clinical trial evaluating the effectiveness of an arginine degrading enzyme agent called ADI-PEG 20.…
“We are at a point where in the next few years we’re going to have a lot more options for our patients,” said Dr. Hedy…
This week, Nature Medicine published the results, as well the genomic and immunologic analyses, from the Phase 2 PrE0505 clinical trial. The trial, which took…
A phase 3 randomized clinical trial looking into the efficacy of combination chemotherapy with immunotherapy is now open in the United States and Australia. How…
The challenges of treating mesothelioma are well known to this community of patients, caregivers, bereaved, and the physicians who treat them. Particularly, researchers have been…
A Phase 3 trial in relapsed mesothelioma patients showed a significant improvement in overall survival and progression-free survival when patients were treated with nivolumab. Nivolumab…
Marjorie G. Zauderer, MD, discusses a currently enrolling Phase 1 clinical trial for mesothelioma patients. This CAR-T cell therapy trial targets mesothelin, a protein heavily…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
